COPERNICO

A RANDOMIZED, CONTROLLED, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB COMBINED WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)-PNEUMONIA WHO ARE UNRESPONSIVE TO STANDARD CARE 

PROJECT DETAILS

COPERNICO PRIMARY OBJECTIVE IS TO ASSESS THE EFFICACY–AS DETERMINED BY THE PROPORTION OF PATIENTS WITH NORMALIZATION OF SPO2 ≥96%– OF CONTINUED STANDARD CARE TOGETHER WITH TOCILIZUMAB PLUS PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH COVID-19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION.  IS A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO-ARM, PHASE II CLINICAL TRIAL IN MEN WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC). 

EXPLORATORY OBJECTIVE IS TO ESTABLISH WHETHER STUDY TREATMENT WOULD ALLOW TO RECOVER T CELL FUNCTIONALITY AND REGULATE CYTOKINE STORM IN PATIENTS WITH COVID- 19 PNEUMONIA WHO ARE NONRESPONSIVE TO FRONTLINE THERAPY WITHIN 48 HOURS FROM TREATMENT INITIATION. 

COPERNICO AT CLINICALTRIALS.GOV

N

SITES

COUNTRY

STATUS

24

8

Spain

Recruiting

COPERNICO SITES

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Hospital Universitario Dr Peset

SPAIN

Hospital Quirónsalud Barcelona

SPAIN

Hospital Universitario Arnau de Vilanova de Lleida

SPAIN

Hospital Ruber Internacional 

SPAIN

Hospital Ruber Juan Bravo

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Hospital Universitari Vall D'Hebron